WHO vaccine-preventable diseases: monitoring system. 2018 global summary

Last updated 15-Jul-2018 (data as of 15-Jul-2018)
Next overall update Winter 2018
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 60'8301 Infant (under 12 months) mortality rate: 22
GDP / capita (US$): 53'5181 Child (under 5 years) mortality rate: 22

Population data in thousands3

  2017  2016  2015  2014  2013  2000  1990  1980 
Total population 335  332  330  328  327  280  255  228 
Births
Surviving infants
Pop. less than 5 years 22  22  23  23  23  21  21  21 
Pop. less than 15 years 67  67  67  67  67  65  64  63 
Female 15-49 years 78  78  78  78  78  72  65  56 

Number of reported cases

(Click for retrospective incidence data for Iceland)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  14  13 
Mumps
ChartChart
  71 
Pertussis
ChartChart
  19  14  31  41 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Iceland)
Vaccine year result method % card seen                                                
BCG         
DTP1          97  96  96  96  97  99 
DTP3          89  91  92  90  91  98  99 
DTP4          91  87  91  84 
IPV1          97  96  96 
HepB_BD         
HepB3         
Hib3          89  91  92  90  91  98 
JapEnc         
MCV1          92  91  93  90  91  91  99 
MCV2          95  95  94  93  94 
MenA         
PCV1          97  96  95  96  96 
PCV2          96  95  94  95  95 
PCV3          88  90  91  90  89 
Pol3          89  91  92  90  91  98  99 
Rota1         
RotaC         
RCV1          92  91  93  90  91 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid July 2019

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Iceland)
DTP1
ChartChart
  97  96  96  96  97  99  99  99 
DTP3
ChartChart
  89  91  92  90  91  98  99  99 
HepB3
 
HepB_BD
 
Hib3
ChartChart
  89  91  92  90  91  98 
MCV1
ChartChart
  92  91  93  90  91  91  99 
MCV2
ChartChart
  95  95  94  93  94 
PCV3
ChartChart
  88  90  91  90  88 
Pol3
  89  91  92  90  91  98  99  99 
RCV1
ChartChart
  92  91  93  90  91  91  99 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country 59  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2017 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibIPV 3, 5, 12 months; Yes
HPV 12 years; +6 months; Yes females only
Influenza_Adult >=60 years; Yes and adults with chronic illness, pregnant women, health care workers, residents living in long-term care facilities, other risk groups
Influenza_Pediatric Yes children with chronic illness
MenC_conj 6, 8 months; Yes
MMR 18 months; 12 years; Yes
Pneumo_conj 3, 5, 12 months; Yes
Tdap 4 years; Yes
TdaPIPV 14 years; Yes

Immunizaton indicators

Indicator Expected answer 2017  2016  2015  2014  2013  2012  2011 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2010-2020  2010-2020  2010-2020         
Nº of districts with microplans that include activities to raise immunization coverage number 59  59  59  59  59  59  59 

System performance

Total Nº districts in country number 59  59  59  59  59  59  59 
Nº districts with DTP3 coverage >=80% number             59 
% of districts with DTP3 coverage >=80% From 0 to 100%             100 
Nº districts with measles (MCV1) coverage >=95% number NA  NA  NA  NA     
% of districts with MCV1 coverage >=95% From 0 to 100%            

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes    Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100% 100  100  100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

 1  "The 2018 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2018, data for 2016
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.